This activity was originally broadcast live as a satellite symposium held in conjunction with HOPA 2022.
Add-on activity
This activity includes video animations.
Program Description
Lung cancer is the most commonly diagnosed cancer and a leading cause of cancer deaths in the United States. Non−small cell lung cancer (NSCLC) associated with exon 20 insertion mutations occurs in approximately 10% of epidermal growth factor receptor (EGFR) mutations and is often resistant to conventional EGFR tyrosine kinase inhibitors. Until recently, there were no targeted therapies available specifically for patients with exon 20 insertion mutations. This activity will review data supporting the use of these new therapies as well as their place in treatment for patients with exon 20 EGFR-positive NSCLC. This program also features video animations detailing the relationship between disease pathophysiology and mechanism of action of the therapies. Considerations for oncology pharmacists surrounding biomarker testing, drug interactions, and managing adverse effects to optimize patient care will also be discussed.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: May 17, 2022
Expiration date: May 17, 2023
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Distinguish epidermal growth factor receptor (EGFR) exon 20 insertion mutations based on pathobiology, prevalence, prognosis, and general treatment strategies
- Explore the pharmacology of novel drugs targeting EGFR exon 20 insertion mutations and their place in the current treatment paradigm
- Investigate opportunities to improve patient outcomes through pharmacist interventions and mitigating toxicities
Josiah Land, PharmD, BCOP
Clinical Pharmacy Specialist
Memorial Sloan Kettering Cancer Center
New York, New York
Brittany Hoffmann-Eubanks, PharmD, MBA
Medical Writer for Animations
Founder and CEO
Banner Medical LLC
Frankfort, Illinois
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-22-110-L01-P. The activity is available for CE credit through June 28, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webinar in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Josiah Land, PharmD, BCOP
Medical Writer for Animations
Brittany Hoffmann-Eubanks, PharmD, MBA
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Rose Buszka, PharmD, BCPS; Liz Rauh; Susan Pordon; Brianna Winters; and Chloe Taccetta
An anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Medical reviewer Kevin Chen, PharmD, MS, has the following relevant financial relationships with commercial interests to disclose:
Advisory Board: Pfizer Inc, Blueprint Medicines
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms